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Abstract
Over the past decade, the role of the ubiquitin–proteasome system (UPS) has been the subject of
numerous studies to elucidate its role in cardiovascular physiology and pathophysiology. There
have been many advances in this field including the use of proteomics to achieve a better
understanding of how the cardiac proteasome is regulated. Moreover, improved methods for the
assessment of UPS function and the development of genetic models to study the role of the UPS
have led to the realization that often the function of this system deviates from the norm in many
cardiovascular pathologies. Hence, dysfunction has been described in atherosclerosis, familial
cardiac proteinopathies, idiopathic dilated cardiomyopathies, and myocardial ischemia. This has
led to numerous studies of the ubiquitin protein (E3) ligases and their roles in cardiac physiology
and pathophysiology. This has also led to the controversial proposition of treating atherosclerosis,
cardiac hypertrophy, and myocardial ischemia with proteasome inhibitors. Furthering our
knowledge of this system may help in the development of new UPS-based therapeutic modalities
for mitigation of cardiovascular disease.
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I. Introduction
The ubiquitin-proteasome system (UPS) is the major nonlysosomal pathway for intracellular
degradation of proteins and plays a major role in regulating many cellular processes. Many
of these processes have already been or will be described in the accompanying chapters. For
the most part, the structure of the 26S proteasome, the immunoproteasome, and the 11S-
activated proteasome have been described in detail in earlier chapters of this book. To avoid
overlap, the sections in this chapter deal exclusively with UPS function and regulation as
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they pertain to the cardiovascular system. The chapter first examines regulation of the
cardiac proteasome followed by an in-depth discussion of the role of the UPS and the
controversial use of proteasome inhibitors in atherosclerosis. A description of the ubiquitin
protein (E3) ligases follows with a discussion of their potential roles in cardiac physiology
and pathophysiology. This leads up to the entire issue of protein quality control (PQC) in the
cardiovascular system and how the UPS functions and malfunctions in both familial
proteinopathies and idiopathic dilated cardiomyopathies (heart failure). The chapter ends
with a discussion of proteasome dysfunction in myocardial ischemia, the potential role of
the UPS in ischemic preconditioning (IPC), and a revisit of the controversial proposed use of
proteasome inhibitors to treat some aspects of ischemia.
II. Regulation of the Cardiac Proteasome
Given the importance of the UPS in cardiovascular physiology and pathology, it was only
natural that the cardiac proteasome would attract the attention of one of the premier
proteomics groups who have conducted an extensive characterization to provide some clues
to the regulation of proteasome function. The following section is a discussion of the
regulation of the UPS as it applies to the cardiac proteasome although it may be applicable
to proteasomes in other cell types as well.
A. Heterogeneity as a Basis for Regulation
Prior to 2005, the prevailing hypothesis was that both β rings of the 20S proteasome were
homologous to each other, that is, both rings had the same distribution of constitutive versus
immunoforms of β1, β2, or β5 subunits. Since then, studies from the Ping group at UCLA
have revealed a rather surprising heterogeneity in at least the β rings.1-4 These investigators
have shown that the total cardiac 20S proteasome population can consist of multiple
subpopulations containing different proportions of the catalytic β subunits, that is, the β1,
β2, and β5 subunits may be replaced by the immunoform on one β ring, but not the other, or
perhaps even a mixture of immunoform versus nonimmunoform subunits. As predicted, the
different subpopulations of the 20S proteasome exhibit unique proteolytic activities, and
specificity and selectivity for various substrates, suggesting a role in regulation of
intracellular proteolysis.3-5 A potential scheme illustrating how proteasomes may be
regulated by heterogeneous configurations is presented in Fig. 1. In regard to the 19S
regulatory particle, alternate splicing of Rpn10 has been reported2 and a recent study
describes isolation of two distinct populations of the 19S regulatory particle from the murine
heart.7 The presence of multiple proteasome subpopulations suggests the potential for
directing assembly to effect selective degradation (or not) of a protein or class of proteins,
possibly altering the outcome of a disease process.
B. Posttranslational Modification and Associating Partners as a Basis for Regulation
These two topics are intimately related and are discussed together. Often, as is the case with
phosphorylation, it is the associating partner of the proteasome that results in the
posttranslational modification. Studies have suggested a dynamic link between the activity
of the proteasome and metabolic demand as glycosylation of the 19S regulatory particle
ATPase, Rpt2, can inhibit ATPase activity and shut down proteolytic activity.8
Phosphorylation of the 19S regulatory particle ATPase, Rpt6, at ser120 by cAMP-dependent
protein kinase A (PKA) is associated with an increase in proteasome proteolytic activities.
Dephosphorylation by the serine threonine protein phosphatase, PP1γ, reverses this.9 Taken
together, these findings suggest that hormones using the PKA system can act in concert with
glucose metabolism to regulate proteasome function.
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In regard to the heart, Ping and coworkers have published a series of studies that have
characterized both the associating partners and posttranslational modifications of the murine
cardiac proteasome and have provided much of the evidence linking PKA-mediated
phosphorylation of multiple proteasome subunits with changes in proteolytic
activity.2,7,10-13 Multiple posttranslational modifications have been described, including N-
terminal acetylation of Rpn1, Rpn5, Rpn6, Rpt3, and Rpt6 of the 19S regulatory particle,
and α2, α5, α7, β3, and β4 subunits of the 20S proteasome; and myristolation of Rpt2. In
addition, phosphorylation of the α1, α2, α3, α6, α7, β2, and β5 subunits was described and
linked to the previously unknown proteasome-associating partner, PKA. Incubation with
PKA increased all three proteolytic activities, which was reversed by incubation with the
serine threonine protein phosphatase, PP2A.2,11-13 Taken as a whole, these studies suggest
that cAMP-dependent PKA plays a central role in regulating proteasome function and
activity, which may be altered in the development of certain cardiac diseases, such as
hypertrophy.10 Based largely on these studies, it was proposed that the cardiac proteasome
may actually be regulated by multiple kinases and may be a component of signal
transduction pathways6 (Fig. 2 presents one possible generic scenario).
For the most part, the cardiac 19S regulatory particle remains a mystery. However, as
pointed out earlier, a recent study has reported isolation of two distinct populations of
cardiac 19S regulatory particles, one of which associates with heat shock protein 90
(HSP90) and has a decreased functional potency.7 Inhibition of the associating HSP90 led to
an enhanced activating potential of this subpopulation of 19S regulatory particles on 20S
proteasomes. While much work needs to be done on regulation of both the 20S proteasome
and 19S regulatory particle, as well as other regulatory particles, it is becoming clearer that
the cardiac proteasome is a dynamic structure under dynamic control, which probably allows
it to respond to rapid changes in cardiac metabolism.
III. Involvement of the UPS in atherosclerosis
Beyond rhetoric, one may therefore wonder about an involvement of the leading cellular
degenerative machinery in the leading human degenerative disease process. Over the past
decade, a number of studies have explored this question and an integrative view is provided
in this section. As the influence of the UPS varies by disease stage, its role in atherosclerosis
is reviewed accordingly (Fig. 3).
A. The UPS in the Initiation Stage of Atherosclerosis
It has been said that atherosclerosis is a disease of the intima of large to medium-sized
arteries with hardening plaque formation. While it has now been realized that the entire
arterial wall undergoes remodeling, traditional teaching still holds true in the sense that the
disease process starts with the lining of the intima, that is, the endothelium. Endothelial
dysfunction and activation presents the first and still reversible event in the atherosclerotic
sequence.14,15 On a molecular level, this disease stage is closely related to reduced
bioavailability of nitric oxide (NO), which can be due to a reduction of NO production and/
or an increase in NO consumption. Over the last few years, exciting discoveries have been
made concerning the influence of the UPS, both under normal and pathological conditions,
on the activity of the enzyme that generates NO in the vascular wall: endothelial NO
synthase (eNOS).
Under normal conditions, eNOS is kept in an inactive state at the cell membrane by
interaction with caveolin-1. Importantly, the posttranscriptional level of eNOS and hence the
relative ratio to caveolin-1 is influenced by the proteasome and possibly favorably altered by
proteasome inhibition.16 In addition to release from caveolin-1 and dimerization, normal
eNOS activity requires Akt-induced phosphorylation, particularly of its serine residue 1179,
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and dephosphorylation of this residue by protein phosphatase 2A leads to eNOS
inactivation.17 Interestingly, both Akt and protein phosphatase 2A are influenced in their
activity by the UPS but seemingly in a different manner. While ubiquitination of Akt leads
to its degradation by the proteasome complex, ubiquitination of protein phosphatase 2A
leads to its translocation from the cytosol to the cell membrane, where it can then interact
with eNOS.17 These differences also highlight the various regulatory influences of the
ubiquitin system on intracellular proteins.18 NO generated by eNOS exerts a broad range of
effects within endothelial and neighboring cells. On the level of the vascular smooth muscle
cells (VSMCs) of the media, NO binds and activates soluble guanyl cyclase (sGC). This
enzyme then generates cGMP from GTP, which mediates VSMC relaxation by various
mechanisms. Importantly, cellular levels of sGC are negatively controlled by proteasomal
degradation following ubiquitination by the co-chaperone/ubiquitin ligase carboxyl terminus
of Hsc70 interacting protein (CHIP).19 For this reason, the effect of proteasome inhibition
on protein phosphatase 2A can prevail over other outlined effects, leading to a decrease in
eNOS activity on endothelial cell level, whereas the overall scenario might be different
when testing organs or organisms.16,17
Cardiovascular risk factors can downregulate eNOS activity and efficacy quite potently. One
key mechanism is depletion of tetrahydro-L-biopterin (BH4), which serves as an essential
cofactor for normal eNOS function. Very intriguingly, under hyperglycemic conditions,
BH4 can become depleted by UPS-dependent degradation of guanosine 5′-triphosphate
cyclohydrolase I.20 Oxidative stress products such as 4-hydroxynonenal (4-HNE) generated
in the setting of exposure to hypercholesterolemia or hypertension can accomplish the
same.21 In the absence of BH4, eNOS generates superoxide anions instead of NO (so-called
eNOS uncoupling).22 By this mechanism, the bioavailability of NO can be reduced quite
quickly as NO is no longer produced and any remaining NO is consumed by superoxide
anions to generate the potent cytotoxin, peroxynitrite. While superoxide anions are the
epitome of oxidative stress in the arterial wall, a number of reactive oxygen and nitrate
species are generated and insufficiencies of antioxidant defense mechanisms have to be
considered as well. One of these involves nuclear erythroid 2-related factor 2 (Nrf2). As
long as the level of oxidative stress is low, this transcription factor is marked for
proteasomal degradation by constitutive ubiquitination, which involves Keap-1 as a
substrate adaptor for a Cul3-dependent E3 ubiquitin ligase complex.23 Under circumstances
of increased cellular oxidative stress, Keap-1 itself undergoes ubiquitination and
proteasomal degradation, which stabilizes Nrf2 then on and allows it to bind to genome
sequences with an antioxidant response element. This leads to the expression of genes
encoding for proteins which have been linked to the amelioration of oxidative stress. Of
note, Nrf2 also leads to an upregulation of proteasome subunits, and their overexpression via
the Nrf2 pathway has been found to increase cellular resistance even against toxic misfolded
proteins.24 Likewise, proteasome inhibitors can “shield” against oxidative injury in an Nrf2-
dependent manner.25 However, this potential is not infinite and, at higher dosages,
proteasome inhibitors can in fact worsen cellular oxidative stress.26 Vice versa, a dual effect
on proteasome function has been shown for oxidative stress products such as oxLDL and
HNE.27,28
Interestingly, there are two other transcription factors whose activation pathways are
stimulated by elevated intracellular levels of oxidative stress with involvement of the UPS.29
The first one is nuclear factor kappa-B (NFκB), and gene sequences controlled by NFκB
include those that encode for vascular cell adhesion molecule-1, E-selectin, and monocyte
chemoattractant protein-1 (Fig. 4).30 These molecules lead to the attraction and
accumulation of inflammatory cells to and in the arterial wall, and hence NFκB is a pivotal
factor for the development of atherosclerosis as an inflammatory disease from its early
stages onward. NFκB also adds to the cell proliferation aspects of atherosclerosis, for
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instance, by regulating the expression of endothelin-1. The second transcription factor to be
mentioned in this context is hypoxia-inducible factor (HIF)-1α (Fig. 5).31,32 Importantly,
HIF-1α adds to and stimulates NFκB activity but remains best known for plaque facilitating
vasa vasorum and then neovascularization.
B. The UPS and Progression Stage of Atherosclerosis
The dysfunctional endothelium with reduced barrier function allows cholesterol, especially
in the form of so-called low-density lipoprotein (LDL) particles, to enter the subintimal
space. In the environment marked by oxidative stress, these particles then undergo various
modifications that lead to their entrapment and uptake by macrophages. An imbalance of
cholesterol uptake and efflux along with suppression of apoptosis leads to the conversion of
macrophages to foam cells. The expression of CD36, a member of the family of scavenger
receptors that mediate the uptake of modified LDL particles, is regulated by protein kinase C
alpha (PKCα). Importantly, ubiquitination of PKCα leads to the downregulation of this
enzyme, CD36, cholesterol accumulation, and development of atherosclerosis.33 On the
other side of the input–output equation, cholesterol efflux from macrophages depends on
ATP-binding cassette transporter molecules (such as ABCA1 and G1), and their expression
level is likewise negatively controlled by the UPS.34 As such, inhibition of the UPS can
yield two opposing effects: increase of cholesterol uptake via CD36 and increase in reverse
cholesterol transport via ABCA1 and G1. A pathway by which the UPS may contribute to
foam cell maintenance is via adipose differentiation-related protein. This protein is
associated with lipid droplets in various cell types including foam cells, and a functional
UPS is required for the regression of these cells.35 Finally, and in fact the very first link
between the UPS and foam cells was provided by the observation that aggregated LDL
particles stimulate the expression of a ubiquitin-conjugating enzyme that mediates the
ubiquitination and degradation of p53, and thereby facilitates the suppression of apoptosis of
lipid-bearing macrophages contributing to foam cell formation.36
As yet another reflection of the evolving disease process, VSMCs invade the subendothelial
space from the media and transform into a proliferating phenotype. They also become
metabolically active and generate the collagen-rich matrix that eventually overlies an
atheromatous lipid pool. This transformation of smooth muscle cells involves extensive
intracellular remolding and is prevented by proteasome inhibitors.30 Myocardin has been
identified as one specific molecular mediator of this process. This transcriptional coactivator
controls the expression of genes for a contractile smooth muscle cell phenotype but is
downregulated by CHIP-mediated ubiquitination and proteasomal degradation.37 Likely
mediated by upregulation of the p21 cyclin-dependent kinase inhibitor, proteasome
inhibitors also inhibit migration and proliferation of VSMCs.38,39 A shift in the balance in
favor of proapoptotic molecules may also contribute to the antiproliferation effects of
proteasome inhibitors.39,40 Under normal conditions, NO may recapture these effects by
inhibitory S-nitrosylation of proteolytic core proteins and modification of proteasome
composition.41 Furthermore, NO inhibits activation of NFκB in VSMCs by interfering with
phosphorylation and thereby ubiquitination and proteasomal degradation of IκBα.42
Importantly, the activation sequence of NFκB as a pivotal contributor to the proliferative
response of the arterial wall can also be modified by deubiquitinating enzymes. Ubiquitin C-
terminal hydroxylase L1 is a prominent example, expressed not only in endothelial cells but
also especially in neointimal VSMCs in an effort to downregulate NFκB activation by IκBα
deubiquitination.43 Cylindromatosis, another deubiquitinating enzyme expressed strongly in
VSMCs, accomplishes the same by acting on TRAF2, a central molecule in the intracellular
tumor necrosis factor (TNF)-α-receptor signaling cascade upstream from IκBs.44
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C. The UPS in the Complication Stage of Atherosclerosis
The developing atherosclerotic lesions can impair blood flow to the extent that it does not
meet the demand of an end organ, leading to recurrent episodes of ischemia. While this in
itself has clinical implications, the greater concern relates to acute (near-) closure of arteries
as a consequence of acute plaque rupture causing acute ischemic events in various vascular
territories. In a simplified equation, the vulnerability of a plaque toward this complication
stage is determined by the relative content of collagen, produced by transformed VSMCs,
and the volume of the lipid pool, generated by degenerating macrophages. Interestingly
enough, the ratio of fibrous cap to necrotic core is influenced by inflammation and
neovascularization at their very shoulder points.
T cells are of utmost importance for these tissue dynamics, and the UPS is, for one, uniquely
involved in the regulation of NFκB activity in these cells.15 Upon T cell stimulation,
covalent attachment of regulatory ubiquitin chains to regulatory protein Malt1 allows
interaction with the IκB kinase (IKK) complex and its paracaspase activity cleaves A20,
which catalyzes the removal of K63-linked ubiquitin and its paracaspase activity cleaves
A20, which catalyzes the removal of K63-chains from Malt1. As such, the balance between
these two proteins regulates the strength and duration of the IKK/NFκB response upon T
cell receptor (TCR)/CD28 costimulation.45 The significance of this activation mode for
atherosclerotic cardiovascular disease has been questioned by the fact that atherosclerotic
plaque T cells often lack the costimulatory receptor CD28.46 However, the significance of
A20 for the attenuation of atherosclerosis has been confirmed in diabetic mice even though
this was not specifically related to the TCR.47 Another negative feedback loop in T cells
involves Bcl10, which promotes activation of the IKK complex that then will phosphorylate
Bcl10 after T cell antigen receptor stimulation and causes its proteolysis via the beta-TrCP
ubiquitin ligase/proteasome pathway.48
T cell activity is also potently regulated by proteasome-mediated activation and nuclear
translocation of the nuclear factor of activated T cells (NFAT). This transcription factor
controls the expression of the activation-associated cell surface receptors CD25, CD28,
CD120b, and CD134 as well as production of interferon (IFN)-γ, TNF-α, and interleukin
(IL)-4 and IL-5.49 Furthermore, T cells can be arrested in the G(1) phase by accumulation of
cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(KIP1) and the disappearance
of cyclin A, cyclin D2, and proliferating cell nuclear antigen.49 These observations were
made in CD4(+) T cells activated by dendritic cells (DCs), which is very relevant as DCs are
particularly prevalent in the neovascularization-rich shoulder areas of complicated and
symptomatic atherosclerotic plaques.50 Importantly, the proteasome is crucial for the
maturation and function of DCs. As a consequence, DCs with impaired proteasome function
fail to stimulate allogeneic CD4(+) and CD8(+) T cells and autologous CD4(+) T cells
sufficiently enough to regulate innate and adaptive immunity.51,52 Moreover, inhibition of
proteasome function also induces apoptosis of DCs via the mitochondrial pathway.53
Similarly, with prolonged inhibition of proteasome function, T cells undergo apoptosis via
the mitochondrial p53 pathway.54,55 Of utmost significance, oxLDL, highly prevalent in
human atherosclerotic plaques, can induce apoptosis of CD4+/CD25+ regulatory T cells in a
time- and concentration-dependent manner.56 Apoptosis of this regulatory T cell population
removes a vital stabilizing force from the atherosclerotic plaque as these cells downregulate
T cell responses to foreign and self-antigens.57
Recently, the immunoproteasome was identified as a potential link between inflammation
and apoptosis of plaque cells.58 In the presence of IFN-γ, fibrous cap VSMCs are sensitized
to apoptosis via the Fas/Fas ligand pathway, which is prevented by interference with the
inducible β5 subunit of the immunoproteasome. As it was subsequently realized, a switch to
the immunoproteasome allowed proteolytic processing of myeloid cell leukemia (Mcl)-1,
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thereby removing a potent inhibitor (sequester) of proapoptotic molecules.59 Intriguingly,
this mode of regulation is in addition to the possible degradation of Mcl-1 via the
conventional UPS.60 These observations indicate that even subtle nuances in proteasome
composition and activity may be important for the phenotype of biological and
pathobiological processes.
In addition to apoptosis, autophagic cell death has been reported in atherosclerotic plaques
with potentially detrimental consequences.61 Autophagy is activated under circumstances of
impaired proteasome function likely as a consequence of endoplasmic reticulum (ER) stress
and as a compensatory effort to remove polyubiquitinated protein aggregates.62 However, a
number of other mechanisms can induce autophagy in the atherosclerotic plaque, not related
to impairment of proteasome function.61 Furthermore, autophagy can also have
cytoprotective effects and the detrimental effects prevail only with excessive stimulation of
autophagic activity.61
D. Proteasome Inhibition and Atherosclerosis: For Better or for Worse?
Utilizing a murine carotid collar of atherosclerosis, a 4-week treatment course with the
proteasome inhibitor bortezomib, given once every 3 days at either a low- or high-dose
regimen (corresponding to nearly 40% and 60% proteasome inhibition in the aorta,
respectively), did not influence the composition of early plaques but led to a significant
increase in necrotic core area and apoptotic cells as well as a decrease in VSMCs and
collagen content in advanced atherosclerotic plaques (Fig. 6).63 Most intriguingly, compared
with carotid artery plaques from patients who did not have symptoms of focal cerebral
ischemia within 6 months of carotid endarterectomy, plaques from symptomatic patients
were characterized by lower collagen content and increased rate of apoptosis.64 In
correlation with the latter, the level of ubiquitination was higher and the level of proteasome
activity was lower in symptomatic plaques (Fig. 7). Demonstrating that proteasome function
can intrinsically decline in atherosclerosis with the potential to propagate plaque dynamics
toward an unstable phenotype, these observations provided further insight into the functional
significance of the original observation of elevated ubiquitin levels in advanced and
complicated coronary artery plaques of patients with acute myocardial infarction (Fig. 8).66
It has to be acknowledged though that some studies demonstrated an increase in proteasome
activity in high-risk plaques, macrophages extracted from these plaques, and even peripheral
monocytes.67-69 These contradictory results may be explained by differences in the
composition of the study population, as subsequent studies did indicate that proteasome
activity was lower in atherosclerotic plaques of patients older than 60 years of age.70
Intriguingly, an age-dependent decrease of proteasome function has been shown in other
organs including the heart.71,72 Hence, a decline in proteasome function may become a
prevailing phenomenon over time with the consequences outlined above.
Similar to the debate in advanced atherosclerotic plaques, experimental studies in early
atherosclerosis have yielded conflicting results. In agreement with the detrimental effect of
the UPS on BH4 levels and NFκB activation, proteasome inhibitors or drugs that have
proteasome-inhibitory potential such as aspirin were found to improve endothelial function
and structural alterations of atherosclerosis in hypercholesterolemic and uremic rabbits as
well as diabetic mice.16,20,73,74 On the contrary, we noted a remarkable deterioration
endothelial function and aggravation of atherosclerosis in pigs on a normal or a high-
cholesterol diet undergoing chronic proteasome inhibitor administration (Fig. 8).18 One
readily notable difference between these studies is that boronate-type proteasome inhibitor
used in our study is more proteasome-specific and selectively inhibits chymotrypsin-like
activity whereas the peptide aldehyde MG132 is not as proteasome and proteasome subunit
specific. conclusions on the functional significance (beneficial or detrimental) of
upregulation of proteasome activity under pathological conditions which been consistently
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outlined in all of these studies therefore remains confounded by the inherent limitations of
using various proteasome inhibitors. Currently, there is agreement that proteasome inhibitors
can be “poisons or remedies” depending on the context in which they are used.75
E. Summary: The UPS and Atherosclerosis
This section reviews the current and most up-to-date knowledge of the UPS in
atherosclerosis with the following key points: First, the UPS is variably involved in the
regulation of eNOS activity and modulation of oxidative stress, which is highly relevant for
the initiation stage of atherosclerosis and beyond. Second, the UPS plays a central role in the
activation pathway of NFκB in various cells, mediating adhesion molecule expression,
cytokine release, and proliferation. Moreover, it can influence foam cell formation and
maintenance, both of which influence atherosclerosis progression. Third, contrary to the
initiation and progression stage, the complication stage of atherosclerosis seems to be linked
to a reduction of proteasome activity mediated by accumulating levels of oxidative stress in
aging cells over time. In this, atherosclerosis shares similarities with neurodegenerative
disorders and protein quality diseases. Indeed, the UPS and particularly the proteasome
complex is a vital component of PQC mechanisms as it prevents the accumulation of
dysfunctional proteins, which can be toxic to the cell and its environment (Fig. 9).36 As
such, preservation rather than inhibition of proteasome function should be the goal while
acknowledging some clear-cut exceptions and nuances. For instance, transient and reversible
low-level proteasome inhibition has clearly been shown to exert beneficial effects such as
increasing the resistance of cells against oxidative stress. The key is that this type of
proteasome inhibition can be understood as a conditioning rather than an inhibition regimen
similar to the protective effects of cardiac preconditioning.26 Otherwise, a more local and
focal mode of proteasome inhibition is to be favored such as the use in drug-eluting stents.
Particularly advanced plaques may become vulnerable with systemic general proteasome
inhibitor administration. In the coming years, further details of the function and significance
of the UPS in atherosclerosis will likely be revealed that will hopefully lead to the
development of novel strategies.
IV. The Role of Cardiac E3 Ligases
A. Pathologic Cardiac Hypertrophy
The role of the UPS, and specifically cardiac E3 ligases, in the development of pathologic
cardiac hypertrophy is now well appreciated. Pathologic left ventricular hypertrophy is
induced by a variety of factors (such as ischemia and volume or pressure overload) and
results in a concomitant increase in both protein synthesis and proteolysis, the latter of
which is regulated in large part by the UPS.76,77 Following the induction of pathologic
cardiac hypertrophy, the mRNA levels of ubiquitin, E1, E2, and E3s (specifically atrogin-1
and MuRF1 (muscle ring finger 1)) increase.78 A similar increase in transcriptional
upregulation of atrogin-1 and MuRF1 occurs in an in vivo model of chronic heart failure
(CHF), indicating that cardiac E3 ligases are involved in both the development and end-
stage pathology associated with pathologic cardiac hypertrophy. Although there is still some
doubt as to whether or not these increases in expression of atrogin-1 and MuRF1 are
beneficial in the defense against pathologic cardiac hypertrophy, as will be detailed in the
following sections, the evidence suggesting that these cardiac E3 ligases are pivotal in
regulating the development of cardiac hypertrophy is accumulating.
1. Atrogin-1—Cardiac atrogin-1 (also known as MAFbx1) is a cardiac and skeletal
muscle-specific F-box protein first identified as a crucial participant in skeletal muscle
atrophy programs.79,80 The expression level of atrogin-1 is tightly regulated at the
transcriptional level in both skeletal myocytes and cardiomyocytes by members of the
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Forkhead family of transcription factors.81,82 As with all cardiac E3 ligases elucidated thus
far, atrogin-1 has generalized antihypertrophic activity, and is able to inhibit cardiac
hypertrophy induced by either pathologic or physiologic stimuli. In the case of pathologic
cardiac hypertrophy, atrogin-1 works as a cardiac E3 ligase and targets the “pro-
hypertrophy” protein calcineurin for proteasomal degradation.83 Calcineurin is a calcium/
calmodulin-activated serine/threonine phosphatase that is a critical component of the
signaling pathway that promotes pathologic hypertrophic growth of cardiomyocytes.84
Calcineurin initiates nuclear signaling by dephosphorylating the NFAT transcription factor,
which in turn activates transcription of hypertrophy-associated genes. Atrogin-1 inhibits this
calcineurin-dependent transactivation and downstream NFATc4 translocation by serving as
an adaptor for calcineurin to associate with Skp1, Cul1, and Roc1 (the common components
of SCF ubiquitin ligase complexes) to assemble an SCF (atrogin-1) E3 complex that
ubiquitinates calcineurin and targets it for proteasome-dependent degradation.85 By
targeting calcineurin for proteasomal degradation (and thereby inhibiting NFAT
transcriptional activation of hypertrophy-associated genes), atrogin-1 disrupts a critical
signaling pathway involved in pathologic hypertrophy.83,86 In addition to its ability to
inhibit pathologic cardiac hypertrophy, atrogin-1 can also decrease cardiac hypertrophy
induced by physiologic stimuli. In this case, however, atrogin-1 uses a completely different
mechanism of action. In response to the induction of physiologic cardiac hypertrophy,
atrogin-1 targets the transcription factors Foxo1 and Foxo3 for ubiquitination.87 Surprisingly
though, instead of targeting the Foxo proteins for proteasomal degradation, atrogin-1-
mediated ubiquitination results in enhanced Forkhead transcriptional activity and subsequent
inhibition of Akt-dependent induction of hypertrophy.88 Atrogins’ ability to stimulate Foxo
activity through ubiquitination is by virtue of the fact that atrogin-1 mediates the
noncanonical addition of ubiquitin molecules on the Foxo proteins via lysine-63-linked
chains, as opposed to the traditional canonical lysine-48.87 Previous reports have
documented the ability of lysine-63-linked chains to modulate protein function89,90;
however, the atrogin-1-mediated noncanonical ubiquitination of the Forkhead transcription
factors is the first report of this form of regulatory mechanism working within the heart.
2. MuRF Proteins—The MuRF family of proteins comprises three members: MurF1,
MuRF2, and MuRF3. All these proteins have ubiquitin ligase activity and localize to the M-
line and Z-disc of the sarcomere91-93 where they function, in part, as mechanical stress
sensors via their direct and indirect interactions with the giant protein titin.85,94,95 Although
all three MuRF proteins appear to play an important role in various aspects of myogenic
responses and contractile regulation,96 only MuRF1 appears to be involved in the regulation
of skeletal muscle atrophy and inhibition of pathologic cardiac hypertrophy.97 Although the
mechanism by which MuRF1 mediates cardiac atrophy has not yet been fully elucidated,
recent evidence suggests that MuRF1 may be instrumental in the initial proteolytic
breakdown of the myofibril,98 which then exposes the individual myofibrillar component
proteins to subsequent proteolytic degradation. In cardiac muscle in vitro, MuRF1 exerts E3
ligase activity by ubiquitinating the sarcomeric protein cardiac troponin I, thereby
contributing to its proteasomal degradation.99 However, there are other ways in which
MuRF1 may also contribute to the regulation of cardiac atrophy. For example, in cultured
cardiomyocytes, MuRF1 inhibits PKCε activity through interactions with RACK1, the
receptor for activated protein kinase C protein, which in turn suppresses focal adhesion
kinase and ERK1/2 in cardiomyocytes, resulting in the suppression of cardiomyocyte
hypertrophy.100 It has also been suggested that MuRF1, through its association with the
transcription serum response factor, is involved in a circuit that links mechanical force
generation to transcriptional responses in cardiomyocytes, resulting in hypertrophic
growth.97 In vivo, MuRF1 has been linked to the regulation of cardiac hypertrophy in both
mouse models and human disease.101 MuRF1 protein levels are increased in human cardiac
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tissue isolated from patients undergoing therapeutic atrophy following placement of a left
ventricular assist device (LVAD) as a treatment to decrease pressure overload associated
with heart failure.101
B. Protection Against Ischemic Heart Disease
The cardiac pathology profile associated with ischemic injury centers around the induction
of cardiomyocyte apoptosis. A major player in this ischemia-related cardiomyocyte
apoptosis is the transcription factor p53. p53 target genes include PUMA, Bax, and Apaf1,
each of which plays a distinct yet complementary role in the apoptotic signaling pathway.
Numerous reports have now demonstrated that p53 is a target substrate of multiple cardiac
E3 ligases such as CHIP, murine double minute (MDM) 4, and MDM2. These cardiac E3
ligases ubiquitinate p53 and target it for proteasomal degradation, thereby decreasing
cardiomyocyte apoptosis and resulting in an overall cardioprotective effect in response to
ischemic injury.
1. CHIP and MDM2—The E3 ligase/co-chaperone CHIP (carboxyl terminus of Hsp70-
interacting protein) is highly expressed in cardiac muscle where it ubiquitinates specific
proteins, targeting them for degradation by the 26S proteasome. CHIP is also characterized
by its ability to bind the HSPs Hsc70–Hsp70 and Hsp90. Much of what is known about
CHIP’s cardioprotective function during ischemia/reperfusion injury comes from studies
carried out in CHIP−/−mice. CHIP−/−mice are far more susceptible to cardiac damage
following an ischemic insult compared to wild-type mice, exhibiting a 50% larger infarct
area compared to wild-type controls.102 In addition, CHIP−/−mice exhibit a marked increase
in frequency of arrhythmias following reperfusion, indicating an increased degree of cardiac
damage compared to wild-type mice.102 CHIP-deficient cardiomyocytes also undergo
enhanced apoptosis following ischemia/reperfusion injury, indicating that CHIP inhibits
apoptosis during cardiac stress. The mechanism through which CHIP exerts this
antiapoptotic effect could be linked to the fact that CHIP interacts with both wild-type and
mutant forms of p53. In response to CHIP suppresses the aggregation and stress,
ubiquitinates both forms of p53, leading to their 26S proteasome-dependent degradation.103
This in turn would decrease the ability of p53 to stimulate proapoptotic pathways.
MDM2 is another E3 ligase present in cardiac muscle that regulates the activity and
degradation of proteins such as p53 and Apoptosis Repressor with Caspase recruitment
domain (ARC), both of which are involved in cell growth and apoptosis. Similar to CHIP,
MDM2 inhibits p53 transcriptional activity through ubiquitination and subsequent
proteasomal degradation.91,104,105 In cardiomyocytes, the decrease in p53 levels as a result
of MDM2 ubiquitination leads to an inhibition of apoptosis during pathologic stress.100
Conversely, if MDM2 is inactivated in cardiomyocytes, the level of p53 increases, resulting
in enhanced I/R-induced apoptosis and a subsequent reduction in left ventricular function.100
In addition to targeting p53, MDM2 also regulates ARC protein levels in cardiomyocytes.106
MDM2-mediated ubiquitination of ARC leads to proteasomal degradation of ARC and
subsequent inhibition of cardiomyocyte apoptosis. Recently, the MDM2 homologue MDM4
has been shown to also inhibit p53 in cardiomyocytes. Interestingly, a conditional MDM4
knock-out mouse model demonstrated that decreased cardiac MDM4 levels result in the
development of a dilated cardiomyopathy.107 The cause of this dilated cardiomyopathy was
linked back to a p53-dependent decrease in cardiomyocyte number, indicating the
importance of MDM4 inhibition of p53 activity in fully differentiated cardiomyocytes.
While MDM4 has been shown to have overlapping functions with MDM2, its role in
ischemia/reperfusion injury has not yet been elucidated.
Powell et al. Page 10













2. MuRF3—MuRF3 is another muscle-specific RING finger protein that was originally
identified by its interaction with microtubules and its role in skeletal myoblast
differentiation.93 However, more recent work has expanded the role of MuRF3 to include
activities within the heart. Mice lacking MuRF3 exhibit abnormal sarcomere structure and
have a dramatically increased response to ischemia/reperfusion injury compared to wild-
type mice. When these mice are challenged with ischemia/reperfusion injury, rapid left
ventricular dilation, cardiac rupture, and myocyte degeneration occur within days of the
initial insult.108 Two substrates of MuRF3 have been identified as being γ-filamin and the
four-and-a-half LIM domain protein (FHL2) and the expression of both these proteins is
increased in the hearts of mice lacking MuRF3. Given the dramatic response of MuRF3-
deficient mice to myocardial infarction, it has been suggested that MuRF3-dependent
turnover of γ-filamin and FHL2 is essential to the integrity and function of the heart
following acute ischemic events.108 MuRF3 also plays a role in the regulation and turnover
of sarcomeric contractile proteins including MHCIIa and beta/slow myosin heavy chain, a
function that MuRF3 shares with MuRF1.108 This cooperative relationship between MuRF1
and MuRF3 is illustrated by the pathological phenotype expressed by mice deficient in both
proteins. MuRF1/MuRF3 knockout mice develop a skeletal muscle myopathy and
hypertrophy cardiomyopathy in which myofiber fragmentation, MHC accumulation, and
diminished muscle performance are also seen.109 These findings reveal a critical role for
MuRF1 and MuRF3 in proteasomal-dependent turnover of sarcomeric proteins and suggest
a potential mechanism for the development of myosin storage myopathies.108
C. The UPS in Familial Hypertrophic Cardiomyopathy: Proteasomal Involvement Without
an Identified Cardiac E3 Ligase
While cardiac E3 ligases have been definitely linked to the regulation of cardiac hypertrophy
and ischemia/reperfusion injury, there are other cardiovascular conditions that are known to
involve the UPS, but for which a candidate ubiquitin ligase has yet to be discovered. One
example is familial hypertrophy cardiomyopathy (FHC). FHC is an inherited cardiac disease
that is transmitted as an autosomal-dominant trait. It is estimated that FHC affects 0.2% of
the population and is the major cause of sudden death in young, healthy individuals.110 Over
200 mutations associated with FHC have been identified in 14 different genes, with the
majority of them involving genes encoding sarcomeric proteins.111 Genetic analysis of
families with FHC has revealed that most of the FHC-related mutations occur in the myosin-
binding protein-C (cMyBP-C).112 cMyBP-C is a critical constituent of sarcomeric thick
filaments and has both regulatory and structural roles within the sarcomere. cMyBP-C
interacts with myosin, titin, and actin, which, once again, are essential components of the
sarcomeric apparatus.110-113 Recently it has been demonstrated that the UPS rapidly targets
naturally occurring mutations in cMyBP-C that result in a truncated protein for degradation.
The increase in proteasomal workload associated with clearing of these mutated forms of
cMyBP-C results in impairment of proteolytic capacity.114 Frameshift mutant cMyBP-C
proteins are expressed at markedly lower levels in muscle, despite the fact that the mRNA
levels of these mutant forms of cMyBP-C match the wild-type cMyBP-C mRNA levels,114
in both humans115,116 and transgenic mice.117,118 Experimentally, if the 26S proteasome is
inhibited, expression of the truncated cMyBP-C mutant protein increases to that of wild-type
cMyBP-C levels, supporting a role for proteasomal degradation in the control of cMyBP-C
protein expression levels. Paradoxically, although the UPS is activated to remove mutant
cMyBP-C proteins from the cell, over time, the increased proteasomal workload associated
with this quality control mechanism results in a breakdown in activity of the proteasome,
ultimately leading to the accumulation of mutated cMyBP-C proteins.114 As such, truncated
cMyBP-Cs act as both substrates of the UPS and obstructers of the proteolytic process, a
dichotomy that is shared with certain protein mutants that accumulate in Alzheimer’s
disease and other storage-related neurological conditions.119 The specific E3 ligases that
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target either wild-type or mutant cMyBP-C are currently unknown. If these E3 ligases could
be identified, however, it would be possible to use them as therapeutic targets to alter the
severity and progression of FHCs. The role of the UPS in PQC as it relates to cardiac
proteinopathies is covered in detail in the next section.
D. Summary: Cardiac E3 Ligases
As highlighted in this section, cardiac E3 ligases such as atrogin-1, CHIP, MDM2/4, and
MuRF proteins play a pivotal role in regulating the molecular pathways underlying
cardiovascular conditions such as cardiac hypertrophy and ischemic heart disease.
Furthermore, proteasomal involvement has been reported in a number of other
cardiovascular conditions, such as familial cardiac hypertrophy, although the identity of the
participating cardiac E3 ligases remains unknown. However, despite the potential that
cardiac E3 ligases have as therapeutic agents, more data need to be gathered in order to
understand the extent to which these ligases control various cellular processes, both
beneficial and detrimental. Such focus will allow identification of which cardiac E3 ligases
might serve as therapeutic targets in the future.
V. The UPS in PQC and Cardiac Proteinopathy
A. Cardiac PQC
For a polypeptide to fulfill its normal duty in the cell, it must attain and maintain its native
conformation via proper folding. A misfolded or unfolded protein is not only unable to
perform its normal function, but it is also likely to be detrimental to the cell. PQC is a set of
cellular mechanisms to keep the level of misfolded/unfolded proteins in the cell to the
minimum. All proteins targeted to the secretory pathway go through the ER and are folded
in the ER, while the folding of other proteins, such as cytoskeletal and cytosolic proteins,
does not involve the ER. Hence, PQC is often divided into ER-associated PQC with which
the unfolded protein response is associated, and ER-independent PQC. Given that myofibrils
take the majority of space in the cardiomyocyte and that myofibrillar proteins are not folded
via ER, ER-independent PQC takes care of more proteins in cardiomyocytes than the ER-
associated PQC. Unfortunately, ER-independent PQC is much less understood than ER-
associated PQC. Nevertheless, ER-associated and ER-independent PQC share the same
general principle. Both are carried out by an intricate collaboration between molecular
chaperones and targeted protein degradation. The latter is primarily performed by the
UPS.113 Both genetic mutations and environmental stress can give rise to misfolded protein
molecules. In the cell, misfolded/unfolded proteins, which inevitably expose hydrophobic
surfaces, will be sequestered by molecular chaperones to prevent aberrant aggregation and,
in some cases, to help the misfolded/unfolded proteins to refold. If the refolding is
unsuccessful, the misfolded proteins will then be known as terminally misfolded proteins
and removed by proteasome-mediated degradation. Misfolded proteins that escape from the
surveillance of chaperones and the UPS form aberrant aggregates. Recent evidence suggests
that the autophagic–lysosomal pathway may also contribute to the removal of misfolded
proteins, especially the aggregated form of misfolded proteins (Fig. 9).120
With a few exceptions, misfolded polypeptides are polyubiquitinated before they can be
recognized and degraded by the proteasome. A mature degradation signal, known as a
degron, on the protein molecule is required to trigger the polyubiquitination and subsequent
proteasome-mediated degradation of the protein. For a native protein, the maturation of its
degradation signal is highly regulated and determines when it will be ubiquitinated;
therefore, the degradation of a native protein is primarily determined by the ubiquitination
step. Protein misfolding can either expose encrypted degrons or form a degron de novo (e.g.,
hydrophobic surfaces)121; therefore, it is conceivable that terminally misfolded proteins
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“automatically” activate the ubiquitination system and the rate-limiting step likely resides in
the proteasome-mediated degradation step. Consistent with this notion, the accumulation of
ubiquitinated proteins appears to be a common feature in the cells or tissues with increased
production of misfolded proteins, and enhancing proteasome function facilitates the
degradation of misfolded, but not native, proteins in the cell.122,123 Therefore, measures to
evaluate proteasome functional sufficiency, as well as means to enhance proteasome
function, in a cell or organ are vital to the investigation into the role of the UPS in PQC and
in the genesis of disease caused by misfolded proteins.
Proteasome peptidase activity assays provide a simple method to estimate changes in the
proteolytic activity intrinsic to either the 20S or arguably the 26S proteasome in a crude
protein extract, in a proteasome-enriched preparation from cells or tissue specimens, or in
intact cells or tissues.123 However, these assays do not assess whether the proteasome
proteolytic activity is sufficient or not for adequate PQC in a given cell, tissue, or organ. To
circumvent this deficit, full-length fluorescence proteins modified by fusion with a degron
have been successfully adopted as surrogate substrates for the proteasome. Stable cell lines
and stable transgenic mouse models that constitutively express such surrogate protein
substrates have been established and employed to probe UPS functional status in the cell or
organ in situ.124-126 Regarding the usefulness of these surrogate protein substrates in the
research into PQC and proteinopathy, GFPu/GFPu and GFPdgn are arguably the most
interesting and widely used ones. Both GFPu and GFPdgn were engineered via carboxyl
fusion of degron CL1 to the enhanced green fluorescence protein (GFP). Conventional GFP
is not an effective substrate of the UPS, with a long half-life when expressed in mammalian
cells. The fusion of degron CL1 renders GFP a specific substrate for the UPS.124 Amino
acid replacement experiments showed that degron CL1, a consensus ubiquitination signal
sequence from fission yeast,127 triggers ubiquitination likely by forming a hydrophobic
surface in its helical structure.128 Hence, GFPu and GFPdgn are surrogates for misfolded
proteins because surface exposure of hydrophobic residues is a conformational signature of
misfolded proteins.120 Changes in GFPu/GFPdgn protein levels in the absence of alterations
in their synthesis inversely reflect the capacity of the UPS to remove misfolded proteins.
Emerging evidence suggests that proteasomes with a certain composition may be more
efficiently equipped to degrade misfolded proteins. For instance, it is well known that viral
infection or IFN stimulation triggers the replacement of conventional peptidase subunits (β1,
β2, and β5) in 20S proteasomes with the inducible subunits (β1i, β2i, and β5i) and thereby
upregulates immunoproteasomes.129 A recent study has demonstrated that
immunoproteasomes help the cell to more effectively remove oxidized proteins formed by
increased oxidative stress induced by IFN.130 It was also reported at almost the same time
that upregulation of 11S proteasomes via overexpression of PA28α enhances proteasome-
mediated removal of misfolded proteins and protects against oxidative stress in cultured
cardiomyocytes.131
B. Proteasome Functional Insufficiency in Cardiac Proteinopathy
Proteinopathies are a family of diseases caused by misfolded proteins and featured by the
presence of aberrant protein aggregates in the cell. The best-studied cardiac proteinopathy is
perhaps desmin-related cardiomyopathy (DRC).132 DRC is the cardiac manifestation of
desmin-related myopathy (DRM). DRM is a group of heterogeneous myopathies with a
hallmark of the presence of desmin-positive aberrant protein aggregates in muscle cells.
Mutations in the desmin gene, the aB-crystallin gene (CryAB), and a few other genes whose
products interact with the desmin filaments have been linked to DRM.132 DRM can affect
all three types of muscle: skeletal, cardiac, and smooth muscle. DRC is the main cause of
death of DRM patients. In the past decade, a few DRC mouse models have been created
through cardiac-specific transgenic expression of a DRM-linked mutated gene,133,134 such
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as a missense (R120G) mutant of CryAB (CryABR120G) and a 7-amino-acid (R173 through
E179) deletion mutant of the desmin gene (D7-Des).135,136 Both CryABR120G and D7-des
transgenic mice recapitulate the main aspects of pathology observed in human DRC,
including the presence of desmin-positive protein aggregates in cardiomyocytes and cardiac
dysfunction133,134; hence, these mouse models provide useful platforms for studying DRC
pathogenesis and exploring therapeutic strategies.113,132
Studies with cross-breeding GFPdgn mice with the mouse models of DRC showed marked
increases of GFPdgn protein levels but not GFPdgn transcript levels in mouse hearts
overexpressing either CryABR120G or D7-des,137,138 indicating UPS functional
insufficiency in DRC hearts. The abundance of total ubiquitinated proteins was significantly
increased in the DRC hearts, suggesting that UPS insufficiency is primarily caused by
proteasome functional insufficiency (PFI). Further analyses revealed that the insufficiency
resides mainly in the step delivering ubiquitinated proteins into the 20S proteasome as
decreased protein abundance of critical 19S proteasome subunits, namely Rpt3 and Rpt5, is
concurrently associated with the PFI while the peptidase activities of the 20S proteasome are
not decreased. Further studies have determined that aberrant protein aggregation is in part
responsible for PFI in DRC hearts.137,139 These are highly significant discoveries because
although DRC per se is not a common disease, the DRC mice represent valuable models for
pathogenic elucidation and therapeutic exploration of cardiac proteinopathies. It is
increasingly suggested that a large subset of common heart diseases share likely pathogenic
mechanisms with cardiac proteinopathy. Aberrant protein aggregates are also observed and
considered the trigger of autophagy activation in the pressure-overloaded mouse heart.140
Significant increases in myocardial ubiquitinated proteins have invariably been reported in
studies using this experimental method, although some of the reports dispute the direction of
changes in the proteasome peptidase activities as well as the effect of systemic proteasome
inhibition on the hypertrophic responses and function of pressure-overloaded hearts.141,142
Both the accumulation of aberrant protein aggregates and elevated levels of ubiquitinated
proteins are consistent with PFI but the sufficiency of proteasome function in a pressure-
overloaded or ischemic heart has not been directly assessed yet. A very high prevalence of
aberrant protein aggregates in the form of preamyloid oligomers in human hearts with end-
stage heart failure of common etiologies has been recently reported.143,144 The coexistence
of increased ubiquitinated proteins with aberrant protein aggregation signifies PFI and
serves potentially as a cause of proteasome impairment. Hence, these observations place a
large subset of CHF into the category of cardiac proteinopathy. A better understanding of
the molecular pathogenesis of cardiac proteinopathy should shed light on the molecular
mechanisms by which these heart diseases progress to CHF.
C. PFI Contributes to the Genesis of Proteinopathy
PFI has been observed or implicated in a variety diseases, of diseases, such as neural
degenerative cardiac proteinopathy, and more recently, a large subset of CHF. However,
until very recently, a proteasome activator was unavailable, so it was difficult to directly test
whether PFI plays a role in the development of any of these diseases. The recent discovery
of a benign measure to enhance proteasome function has instantly changed this situation.
Using cultured neonatal rat ventricular myocytes and human embryonic kidney cells, it was
found that overexpressing PA28α (PA28αOE) stabilizes PA28α and thereby upregulates
11S proteasomes, which destabilizes GFPu, a surrogate misfolded protein substrate for the
UPS,120 without affecting the protein levels of endogenous and ectopically overexpressed
native proteins.122 Therefore, this marks the establishment of the first benign measure to
enhance proteasome proteolytic function in cultured cells. A biological relevance of this
exciting new measure was further demonstrated by testing the effect of PA28αOE on
oxidative stress. Enhancing proteasome function by PA28 OE decreased the abundance of
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protein carbonyls, a widely used marker of oxidized proteins, and the prevalence of
apoptosis in cultured cardiomyocytes triggered by the treatment of hydrogen peroxide.131
These findings suggest that PFI plays an important role in injury by oxidative stress. The
latter represents a major cause of myocardial I/R injury. Additionally, PA28α
overexpression and knockdown were shown to enhance and delay the degradation of
CryABR120G in cultured neonatal rat ventricular myocytes.
To verify whether PA28αOE enhances proteasome function in intact animals, transgenic
mouse lines were created to achieve temporally controllable cardiomyocyte-restricted (CR-
PA28αOE),122 using the “Tet-off” system reengineered by Sanbe et al.145 Mice with CR-
PA28αOE initiated at the perinatal period do not display remarkable changes in the
expression of the fetal gene program, heart function, or cardiac morphology till at least 1
year of age, the longest time observed. Introducing GFPdgn into the CR-PA28αOE mice via
cross-breeding, it was validated that CR-PA28αOE facilitates the degradation of GFPdgn, a
surrogate misfolded protein.126 This is evidenced by a marked decrease in GFPdgn protein
level and the unaltered abundance and unchanged translational efficiency of GFPdgn
transcripts. The effect on GFPdgn protein degradation disappears upon turning off CR-
PA28αOE via administration of doxycycline.122 These experiments mark the establishment
of the first genetic method and the first animal model to benignly enhance proteasome
function in the heart, or any other organs. Taking advantage of this model, Li et al. have
further demonstrated that overexpression of PA28α significantly attenuates aberrant protein
aggregation and cardiac hypertrophy and delays the premature death of mice with transgenic
overexpression of CryABR120G in cardiomyocytes, in a bona fide mouse model of cardiac
proteinopathy.122 Moreover, we demonstrated that CR-PA28αOE protects against
myocardial I/R injury induced by coronary ligation and release in intact mice.122 These
studies prove for the first time that PFI plays an important pathogenic role in myocardial I/R
injury and cardiac proteinopathy in both cell culture and intact animals. It is anticipated that
these exciting discoveries, including the invention of new ways to benignly enhance
proteasome function in a cell and an organ, will facilitate research into the pathogenic roles
of UPS dysfunction and promote the development of new therapeutic strategies to treat a
large subset of diseases, including heart diseases.
D. Potential Mechanisms Underlying the Pathogenic Role of PFI
Conceivably, PFI can impair the heart via a number of mechanisms, such as compromising
PQC and disturbing signaling pathways. Sarcomeres are the most fundamental units of
mechanical function in cardiac and skeletal muscles. An extremely vigorous stoichiometry
among different sarcomeric proteins is followed to form sarcomeres and maintained for
proper function of the sarcomere. The replacement of a damaged sarcomeric protein
molecule with a new one must be accurately coupled with the removal of the damaged one.
The UPS is responsible for the degradation of virtually all myofibrillar proteins. Hence, PFI
in cardiomyocytes will leave defective proteins in the sarcomere that are not replaced in a
timely fashion, and which will undoubtedly reduce the functioning of the sarcomere and
ultimately the mechanical performance of the heart. In this regard, PFI may yield the same
consequence as the genetic mutations of the sarcomeric proteins that are known to cause
inherited cardiomyopathies,146 a major cause of CHF. PFI inevitably accumulates misfolded
proteins and permits aberrant protein aggregation. In both humans and mice, expression of
misfolded proteins and resultant aberrant protein aggregation are sufficient to cause
cardiomyopathy and CHF.147-149 In addition to physical impedance to contraction and
relaxation and structural disruption, aberrant protein aggregates can also be detrimental to
multiple cellular processes. Aggregation-prone proteins can directly interact and inhibit
proteasome proteolytic subunits.150,151 In both cultured cardiomyocytes and intact mouse
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hearts, aberrant protein aggregation has been shown to impair proteasome proteolytic
function,117,137-139,152,153 thereby forming a vicious cycle.
Pathological changes in mitochondrial morphology and function as well as programmed cell
death are often associated with CHF. Mitochondrial malfunction and increased cell death
were observed in the mouse hearts of CryABR120G-based DRC that displays severe PFI
before other cardiac pathology becomes discernible.137,154 Pharmacologically induced
proteasome inhibition has been shown to induce cell death in cultured
cardiomyocytes.125,155 The calcineurin–NFAT pathway is an important signaling pathway
that transcriptionally regulates pathological remodeling of the heart.156 Interestingly,
proteasome inhibition can activate the calcineurin–NFAT pathway and promote maladaptive
growth of cultured cardiomyocytes. NFAT transactivation is increased in the D7-des mouse
heart and proteasome inhibition facilitates the progression of a stressed heart to heart
failure.142 Similar to PFI, the loss of an important chaperone (e.g., HSPB2/HSPB5 double
knockout) can also activate the calcineurin–NFAT pathway in the heart,142,157 suggesting
that PQC inadequacy may play a role in the activation of this pathway during pathological
cardiac remodeling.
E. Improving PQC as a Strategy to Treat Cardiac Proteinopathy
No effective therapies are currently available for treating cardiac proteinopathies. However,
by targeting the molecular pathogenesis of proteinopathy, recent experimental studies have
shown some promise. As described earlier, enhancing proteasome function can protect
against cardiac proteinopathy in mice.122 Additionally, pharmacological agents that behave
as chaperones (e.g., high dose of doxycycline) or as inducers of HSPs (e.g.,
geranylgeranylacetone) have been shown to suppress aberrant protein aggregation in
CryABR120G-based DRC mouse hearts, to improve heart function, and to delay premature
death of the DRC mice,158,159 providing strong evidence that pharmacological chaperones
are promising therapeutic candidates for clinical trials to treat cardiac proteinopathies.
VI. The UPS in Heart Failure
Heart failure is defined “as a complex clinical syndrome that can result from any structural
or functional cardiac disorder that impairs the ability of the ventricle to fill with, or eject,
blood.160” The causes and risk factors of heart failure are many, and include hypertension,
ischemic heart disease, diabetes, obesity, valvular heart disease, and exposure to cardiotoxic
agents.160 As discussed in the previous section, some cases of heart failure are familial and
associated with mutations in various genes encoding for various myocardial proteins
(cardiac proteinopathies), leading to issues with PQC. However, the majority of cases are
idiopathic, where no one cause can be identified. This section describes alterations in the
UPS as it relates to this latter group. As will become apparent, changes in activity of the
proteasome are biphasic and seem to correlate with the severity of the process and thus can
be described as early, studied primarily in animal models, versus late, studied using explants
from human hearts.
A. Alterations in UPS in Early Failure
One of the early manifestations of heart failure is development of cardiac hypertrophy
secondary to ventricular remodeling. This early phase of heart failure development has been
modeled in experimental animals using a variety of initiating events, including transverse
aortic constriction (TAC), permanent left anterior descending artery (LAD) occlusion, and
chronic exposure to hypertrophic agents, such as isoproteronol (ISO). Perhaps the earliest
study was by Depre et al.,161 who used a canine TAC model to show that, as the heart
hypertrophies, the UPS is activated. Increased proteasome activity was associated with
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increased expression of proteasome subunits. This result was confirmed in subsequent
studies in a murine ISO-induced hypertrophy model162 and in cardiomyocytes exposed to
hypertrophic agents.163 This is not to say that these results are not without some
controversy, as at least one study observed that proteasome activities are depressed prior to
the onset of cardiac dysfunction in pressure-overloaded hearts of mice.155 An interesting
observation of these and other studies was that inhibition of the proteasome with any one of
an assortment of proteasome inhibitors decreased the amount of hypertrophy associated with
the initiating event.161-164 Activation of the proteasome was associated with alterations in
the stress-response chaperone H11 Kinase/Hsp22.165 In addition, in mice treated with ISO,
cardiac hypertrophy was associated with increased sensitivity of the proteasome to PKA-
mediated activation, as well as an altered proteasome phosphoproteome.10
While the exact mechanism of proteasome activation is unclear at this time, the involvement
of the UPS in cardiac hypertrophy and remodeling cannot be denied. This can be inferred
from the skeletal muscle literature where it is clear that the proteasome and associated
ubiquitination machinery mediate the breakdown of muscle protein (remodeling) necessary
for exercise-induced physiologic hypertrophy.166-169 Although not studied to the same
extent, it is becoming increasingly clear from experimental models that pathological cardiac
remodeling is also associated with changes in the ubiquitin protein ligases that target
myofibrillar and other cardiac proteins, including atrogin-1 (MAFbx) and Murf-1.94,170,171
A recent study has shown that knockout of atrogin-1 is protective in both TAC and β-
adrenergic-induced cardiac hypertrophy.171 There is a key question that remains to be
answered: What is the difference between the remodeling associated with cardiac
hypertrophy that becomes pathologic and leads to heart failure and the physiologic
remodeling associated with exercise that leads to strengthening and optimized function?
B. Alterations in UPS Function in Late Failure
The availability of human heart tissues to study alterations in UPS function in early heart
failure is extremely limited. This or is not the case when studying late, so-called end-stage,
heart failure, where unfortunately there are ample supplies of explanted human hearts
harvested at transplant. Often, these studies are limited by the availability of control human
heart tissues, which generally are donor hearts originally destined for transplant but not used
for a variety of reasons. Two of the earliest studies investigated for the presence of
ubiquitinated proteins or substrates, indirect measures of UPS function at best, and observed
these to be increased, suggesting dysfunction.172,173 Subsequently, we published the first
comprehensive examination of proteasome function in human end-stage heart failure and
confirmed that proteasome activity is diminished in end-stage failure associated with
increases in ubiquitinated proteins.174 Unloading the heart via the use of an LVAD partially
reversed the proteasome dysfunction.174 This is an observation also reported by another pre-
and post-LVAD study which showed enhanced expression of proteasome subunits.175 It is
of interest that similar results were obtained with markers of autophagy which were also
downregulated following mechanical unloading via LVAD.176 Autophagic and proteasome-
mediated degradation are often considered to be parallel proteolytic systems that respond
inversely to each other, that is, when proteasome activity is decreased, autophagy is
increased, or vice versa.123,177 However, in end-stage heart failure, both appear to be
diminished.174,176
As part of our study, increased protein oxidation products that prompted an examination for
oxidative damage to proteasome subunits were observed.174 Protein carbonylation of at least
one subunit of the 19S regulatory particle, Rpt5, was observed, suggesting that the
dysfunction may be secondary to oxidative damage to the proteasome itself, although one
rather intriguing study suggests that humoral auto-antibodies to proteasomes may be
increased in dilated cardiomyopathy.178 In all fairness, not all studies of human heart
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explants report the same dysfunction. One study reports increased expression of
proteasomes in samples from patients with dilated cardiomyopathy referred for left
ventriculoplasty179; however, proteasome activity was not assessed. Nonetheless, if one
extrapolates from the animal and human studies, a relationship between progression of heart
failure and function of the proteasome can be constructed in which activity initially
increases during remodeling but then diminishes below baseline in end-stage heart failure.
VII. The UPS in Myocardial Ischemia/Reperfusion Injury
Ischemia is defined as reduced tissue perfusion resulting in oxygen deprivation accompanied
by diminished removal of metabolites. From a historical perspective, many of the earliest
studies suggesting that ischemia may result in dysfunction of the UPS actually derive from
the brain literature. These earlier studies report increases in insoluble ubiquitin conjugates in
the mitochondria and decreased 26S proteasome activity in the gerbil cortex and
hippocampus following transient forebrain ischemia.180,181 Other studies have confirmed
these results and provide a link between UPS dysfunction and oxidative stress.182,183 Since
the publication of earlier brain studies, there have been several studies examining UPS
dysfunction following myocardial ischemia.
Dysfunctional postischemic proteasome in the heart was first described by Bulteau et al.,184
who reported decreased proteasome chymotryptic, caspase-like, and trypsin-like activity
accompanied by increased ubiquitinated proteins following 30 min of in vivo LAD artery
occlusion. Despite the decrease in tissue proteasome activity, following purification only the
decrease in trypsin-like activity was observed. In a series of studies, Powell et al.185,186
confirmed this observation in the isolated perfused heart model and also demonstrated that
ATP-dependent proteasome activity is preferentially affected. This suggested defects in 26S
proteasome function which were consistent with increases in myocardial ubiquitinated
proteins. One rather intriguing study187 suggested that short periods of ischemia/reperfusion
may result in selective proteasome dysfunction affecting turnover of specific proteins. This
study took the indirect approach of assessing proteasome function by examining the effects
of proteasome inhibitors on turnover of signaling proteins known to be subject to UPS-
mediated degradation.187 This study must be interpreted with caution as lack of studies of
the ubiquitinated homologues of these signaling proteins makes it difficult to determine the
role of the proteasome. Nonetheless, given the earlier discussion on regulation of the cardiac
UPS and presence of proteasome subpopulations, the differential regulation of protein
degradation proposed in this study is conceivable.
A. Potential Mechanisms Involved in Postischemic Proteasome Dysfunction
Various mechanisms have been proposed to explain the dysfunction; however, two potential
explanations have recently received credible experimental support.
1. Ischemia-Induced ATP Depletion—This mechanism is based on the known
requirement for ATP for 20S proteasome and 19S regulatory particle docking and activation
of the proteasome, as well as for protein ubiquitination.188,189 A recent study suggests that
intracellular ATP levels regulate proteasome activity190 in a biphasic manner; thus, it is
certainly conceivable that depletion of ATP during ischemia191 could be partially
responsible for decreased proteasome activity in the ischemic heart. In fact, this mechanism
has been invoked to explain proteasome dysfunction in both an in vivo canine and ex vivo
isolated rat models of ischemia.192,193 Since both of these studies measured proteasome
activity in the presence of ATP, essentially adding back the nucleotide, the dysfunction
should have been reversed, yet this was not the observed result. At least one study has
shown that, even when measured in the presence of optimal concentrations of ATP, post-
ischemic proteasome activity is diminished.186 Taken as a whole, these studies suggest that
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the dysfunction measured using the standard fluorogenic peptide assays is not related to
ATP depletion; however, this does not rule out the possibility that ATP depletion can still be
a contributing factor to proteasome dysfunction during the ischemic period. It does,
however, suggest a defect in the utilization of ATP by the postischemic proteasome. The
presence of oxidative stress and oxidized cytosolic, myofibrillar, and mitochondrial proteins
in the postischemic heart194-197 has prompted us and others to hypothesize that the many
subunits of the 20S proteasome and its regulatory particles may be targets for oxidative
attack.
2. Oxidative Damage to Proteasome and/or Regulatory Subunits—Oxidative
modification of proteins affects their secondary and tertiary structures resulting in unfolding,
which can lead to loss of function and exposure of hydrophobic patches, which in turn can
lead to increased susceptibility to degradation.198,199 Studies of vulnerability of different
populations of proteasomes (20S vs. 26S) to oxidative damage have shown that exposure of
purified proteasome to oxidants, including peroxynitrite,200,201 hypochlorite, hydrogen
peroxide,202 and 4-hydroxynonenal,203,204 leads to inactivation with the 26S configuration
being approximately 10-fold more sensitive.202 In their original study, Bulteau et al.184
report that several α-type subunits of the 20S proteasome are subject to 4-
hydroxynonelation following ischemia/reperfusion though it was not clear that the
dysfunction was related to the modification of these subunits. Subsequently, they reported
that proteasome purified from rat heart seems to be somewhat resistant to inactivation
requiring concentrations of 4-hydroxynonenal in excess of 100 μM.27 In collaboration with
the Das group,205,206 we have shown that pre-treatment of α-tocotrienol, a Vitamin E
analogue, can preserve postischemic proteasome function with preferential effects on the
ATP-dependent activity. This predilection for the preferential effect of ischemia/reperfusion
on the ATP-dependent activity of the proteasome186,193 coupled with the reported higher
vulnerability of the 26S proteasome to oxidative inactivation207 has led to a suggestion that
subunits of the 19S regulatory particle, which utilizes ATP, may be more sensitive to
oxidative damage than those in the 20S proteasome. In fact, the Rpt3 (S6 ATPase) subunit
has been reported to be sensitive to carbonylation reactions in SH-SY5Y cells exposed to an
oxidative environment.208 Consistent with this report, we have identified Rpt3/Rpt5 as 26S
proteasome subunits significantly carbonylated during myocardial ischemia/reperfusion.209
As indicated in the section on heart failure, this was the same subunit(s) that appeared to be
oxidized in explants from human hearts from patients with end-stage heart failure.174
B. The 11S-Activated Proteasome and Myocardial Ischemia
So far, this section has primarily dealt with the role of the 26S proteasome in myocardial
ischemia. However, as described in an earlier chapter in this book as well as earlier in this
chapter, the 20S proteasome can dock with and be regulated by an additional regulatory
particle, the 11S activator ring. This regulatory particle can dock at either end or in
combination with a 19S regulatory particle at one end (hybrid proteasome). Various forms
of this alternate “zome” exist. If it contains one or more immunoforms of the catalytic
subunits (β1i, β2i, β5i), it is often referred to as the immunoproteasome, which as described
earlier is primarily involved with antigen presentation. If it is docked with a 20S that does
not contain immunoforms, it is called the 11S-activated proteasome, which can remove
oxidized proteins as studies have suggested.210 This suggestion is given credence by the
recent report that forced overexpression of the PA28α subunit in cardiomyocytes results in
increased activity of the proteasome associated with enhanced resistance to an oxidative
stress.131 Moreover, a recent study has shown that cardiac-specific overexpression of the
same subunit increases proteasome activity, improves postischemic function, and decreases
infarct size.132 Previously, we had shown that the proteasome was responsible for removal
of proteins oxidized during myocardial ischemia and that this appeared not to require
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ubiquitin.211 Given the oxidative stress associated with myocardial ischemia197,212 as well
as the reported upregulation of this form of the proteasome in a related cardiomyopathy also
associated with oxidative stress,213 it is conceivable that the 11S-activated proteasome plays
a role in the removal of proteins oxidized during myocardial ischemia. A scheme describing
the proposed functions of the 26S- and 11S-activated proteasomes is presented in Fig. 10.
C. The UPS in IPC
As IPC is usually associated with myocardial ischemia, it is discussed in this section. IPC is
a procedure to decrease vulnerability of the myocardium to ischemia/reperfusion injury via
the prior exposure to short ischemic bursts. IPC tends to result in improved postischemic
hemodynamic function and reduced markers of myocardial injury. The215 current thinking is
that IPC involves preischemic signaling changes that open the inward mitochondrial KATP
channels216 and prevent opening of the mitochondrial permeability transition pore.217 Three
studies192,193,209 have suggested that perhaps the UPS plays a role in IPC by facilitating
some of the associated pre- or postischemic signaling changes.
Since the UPS may become dysfunctional during ischemia, by necessity IPC must in some
way preserve postischemic proteasome function. As was the case with the ischemia studies,
earlier studies of IPC protocols to protect the brain from ischemia/reperfusion had already
examined this. These studies showed less accumulation of protein aggregates and
proapoptotic proteins in the postischemic brain.218-220 One of the earliest studies of the heart
suggested that pharmacologic preconditioning of the myocardium with nicorandil affords
some protection of postischemic function of the proteasome.185 Nicorandil is an agent
thought to open the inward mitochondrial KATP channels221 and thus mimic the effects of
IPC. While all three of convincing these recent studies provide evidence that IPC preserves
postischemic dysfunction of the UPS including improved peptidase activity and less
accumulation of ubi-quitinated or misfolded proteins,192,193,209 they differ in their proposed
mechanisms.
1. Preserved Function of the UPS Improves Degradation of δ Protein Kinase C
During Reperfusion—Inhibition of the pro-death kinase, δ Protein Kinase C (δPKC), is
reported to protect the heart from ischemic injury.222 The pro-survival kinase, εPKC, is
activated and translocated to cardiac mitochondria as a result of IPC.223 Churchill et al.193
have shown that IPC improves postischemic UPS function and alters the ratios of these
kinases to favor tissue survival. They have proposed that the UPS regulates the ratio
between these two kinases because a proteasome inhibitor prevents the effects of IPC on
postischemic function and the ratios of δPKC/εPKC. This is an attractive hypothesis;
however, IPC alters the levels of many pro-survival and pro-death proteins thought to be
regulated by the UPS including PTEN,224,225 IκB,187 and Bax.209 As many diverse
pathways are regulated by the UPS, however important it may be, it is likely that UPS-
mediated changes in δPKC account for only a portion of the protective effects of IPC.
2. Increased PKA-mediated activation of proteasome—Given the regulation of the
cardiac proteasome by PKA (Section II.B above), this theory is highly credible. PKA
phosphorylates several subunits of the 20S proteasome and the 19S regulatory particle9,13
which activates proteasome peptidase activity. Asai et al.192 present convincing evidence
that PKA can enhance docking of the 20S proteasome and 19S regulatory particle(s), and
suggest that IPC results in transient preischemic increases in PKA, which enhance assembly
of the intact 26S proteasome. This then carries over to the postischemic period to explain the
higher peptidase activity of the proteasome observed in the immediate postischemic period.
Unfortunately, because assembly of intact proteasome at this time point was not assessed,
the relationship between the improved function and assembly is not clear.
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3. Decreased postischemic oxidation of 19S regulatory particle subunits—As
described earlier, the Rpt5 subunit, one of the ATPase subunits of the 19S regulatory
particle, was recently described as subject to oxidative modification during myocardial
ischemia.209 One of the observations leading up to an examination of the vulnerability of
19S regulatory particle subunits to oxidative damage was the preferential effect of ischemia/
reperfusion on the ATP-dependent activity of the proteasome.193,209 Divald et al.209 report
decreased postischemic carbonylation of the Rpt5 subunit when the heart was subjected to
an IPC protocol. As the Rpt5 subunit plays pivotal roles in the attachment of the “base” of
the 19S regulatory particle to 20S proteasome α-rings226 and the binding of the 19S particle
“lid” to the base,227 it is conceivable that by decreasing oxidation, IPC improves docking of
these two complexes. However, as this was not examined, it is not clear whether the
improved peptidase activity is related to the decreased oxidation of just this one subunit.
Given the complexity of IPC, it is likely that no one single mechanism accounts for the
protective effect of this procedure on postischemic proteasome function.
D. Proteasome Inhibition in Myocardial Ischemia: for Better or for Worse?
The same controversy that surrounds the proposed use of proteasome inhibitors to treat
atherosclerosis applies to myocardial ischemia. There have been a handful of studies in the
literature suggesting that this strategy may be beneficial. As the use of proteasome inhibitors
in myocardial ischemia has recently been discussed in depth,228 little time will be spent on it
here. Suffice it to say that given the proteasome dysfunction that may be present following
myocardial ischemia, this strategy raises grave concerns229 particularly in light of several
studies230-232 reporting unexpected cardiac toxicity associated with administration of the
proteasome inhibitor bortizomeb (Velcade®) for the treatment of multiple myeloma. This is
not to suggest that proteasome inhibitors could not be of value in treating some of the
problems associated with myocardial ischemia. The problems with the first generation of
proteasome inhibitors centers around their nonspecificity. However, it is conceivable that
second-generation proteasome inhibitors with more selective effects, such as the
immunoproteasome inhibitor ONYX-0914,233 may be of value due to their potential anti-
inflammatory properties. Likewise, we foresee altering degradation of specific proteins
through targeting of specific ubiquitin protein ligases as a viable therapeutic intervention in
the future.
VIII. Concluding Statement
The last 15 years have witnessed a veritable explosion in research surrounding the various
roles and functions of the UPS in cellular physiology and pathophysiology. While often
described as simply a means for the removal of unwanted, damaged, or otherwise unneeded
proteins, nothing could be further from the truth. In reality, in removing proteins the UPS
plays a critical role in regulating many of the intracellular processes necessary for cell
function and survival. Given the absolute requirement for the UPS, it was only a matter of
time before this system was examined for its potential roles in cardiovascular physiology
and pathophysiology. This chapter presents a synopsis of this research. Over the past
decade, there have been many advances in our understanding of how the UPS functions in
vascular and myocardial tissues and we have come to realize that many of the cardiovascular
pathologies are associated with some degree of deviation of UPS function from the norm
(increased or decreased). In many of these pathologies, it is not clear whether UPS
dysfunction caused the primary disease process or is secondary to it, but it is clear that once
the UPS becomes dysfunctional, deterioration is enhanced. However, in the familial
proteinopathies, the dysfunctional proteasome plays a role not only in progression of the
disease, but also, at least in experimental models, in the genesis of the proteinopathy.
Although there is still a relative lack of knowledge, efforts to mitigate cardiovascular
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pathologies by modifying the function of the UPS are promising as recent studies with
genetic models and development of activator and second-generation inhibitors have
produced encouraging results. It is hoped that this chapter will spur research to further our
knowledge of this system and lead to the development of new UPS-based therapeutic
modalities for the mitigation of cardiovascular disease.
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Regulation of 20S proteasomes by assembly of heterogeneous configurations. Under the
influence of γ-interferon, select β-subunits are replaced by their immunoforms, which are
directed by the complete α-rings to form half-proteasomes with specific configurations. In
the example shown earlier, the top half-proteasome has constitutive β2 and β5 subunits and
the β1 subunit has been replaced by the immunoform. The bottom half-proteasome has a
constitutive β1 subunit, but the β2 and β5 subunits have been replaced by their
immunoforms. These two distinctly different half-proteasomes mate to form a mature 20S
proteasome that has a heterogeneous configuration. For the sake of clarity, the involvement
of the chaperones PAC1, PAC2, PAC3, and PAC4, and the maturation factor POMP, are not
depicted here. Modified and reproduced from Ref. 6 with the permission of Walters Kluwer
Health.
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Regulation of proteasome activity by kinase cascades. In this scenario, binding of an agonist
with a cell surface receptor initiates a phosphorylation cascade with an end effector protein
kinase kinase kinase (PKKK) phosphorylating some transcription factor which can then
enter the nucleus and interact with DNA resulting in gene transcription. Phosphorylation of
signaling intermediates, in this case the transcription factor, is often a signal for
ubiquitination and targeting to the 26S proteasome for degradation. To amplify or dampen
the effect of the signaling intermediate, any one of the protein kinases within the cascade
might phosphorylate proteasome subunits resulting in increased or decreased peptidase
activity, which would lessen or enhance availability of the signaling molecule accordingly.
Another possibility would be for the gene product to activate a different protein kinase
(PK1), which would phosphorylate proteasome, resulting in activation and thus decreased
availability of the transcription factor, essentially a form of feedback control. Modified and
reproduced from Ref. 6 with the permission of Walters Kluwer Health.
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Focus overview of the role of the ubiquitin–proteasome system in atherosclerosis. In
general, the ubiquitin system is less vulnerable to changes and its activity remains preserved
throughout the stages of atherosclerosis. On the contrary, proteasome activity seems to be
increased in the initiation and progression stage to meet the increased substrate demand
generated by oxidative stress, heightened metabolic activity, and cell transformation.
Accumulation of oxidative stress and aging of the system likely lead to a decline in
proteasome activity, which is notable in the complication stage along with apoptosis and
autophagy.
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The classical example of NFκB is the heterodimer of p50 and p65 and the classical
activation pathway entails the release from its association with an inhibitory molecule of the
IκB family. Upon exposure of the cell to various stimuli such as increase in oxidative stress,
two specific serine residues are rapidly phosphorylated by the IKK1/2 kinases, whose
activity is coupled to upstream signaling cascades by their association with a third protein
called NFκB essential modulator (NEMO). Once phosphorylated, IκBs undergo degradation
via the ubiquitin–proteasome pathway in the main route of NFκB activation. This is
mediated by initial recognition of phosphorylated IκBs by the β-TrCP component of the
ubiquitin ligase complex Skp1/Cul1/ROC1/F-box protein FWD 1 and subsequent covalent
attachment of multiple moities of ubiquitin to the IκBs. The multi-ubiquitin chain allows
subsequent association with the amino-terminal domain of valosin-containing protein
(VCP), and thereby the targeting of IκBs to the 26S proteasome and the translocation of the
transcriptionally active dimers to the nucleus. Worth noticing is the fact that the very same
IKK/E3 combination is also involved in the generation of p50 (NFκB1) from its precursor
molecule p105 by limited proteolysis, adding to its NFκB activating function. Modified and
reproduced with permission from the European Society of Cardiology.30
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Illustration of the hypoxia-inducible factor (HIF) activation pathway, highlighting
hydroxylation and acetylation of HIF-1α depending on cellular oxygen tension, that is,
normoxia and hypoxia. Hydroxylation of the proline residues 402 and 564 of HIF-1α allows
recognition by the ubiquitin system, and thereby labeling for degradation by the proteasome
complex. Modified and reproduced with permission from the American Heart Association.31
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Illustration of the effects of boronate-type proteasome inhibitor treatment (PSI) in addition
to normal (N) or high-cholesterol (HC) for 12 weeks in domestic pigs. Compared with N, a
60% increase in coronary artery chymotrypsin-like proteasome activity is notable in HC and
a 70% decrease in N+PSI and HC+PSI (panel A). This level of proteasome inhibition causes
oxidative stress on the level of the intima, measurable, for instance, by DHE fluorescence,
indicating in situ superoxide anion production similar to the degree observed in HC (panel
B). Concomitantly, there is a decrease in the vasorelaxation response to the endothelium-
dependent agonist bradykinin although more pronounced in PSI pigs (panel C). Along with
endothelial dysfunction, intimal thickening develops in N+PSI similar to HC (panel B). Yet,
even with a similar level of endothelial dysfunction, intimal thickening is greatly aggravated
in HC+PSI. These observations suggest that, while chronic proteasome inhibition can be
harmful under otherwise normal conditions, the consequences are much worse when it
entails blunting a compensatory increase in proteasome activity. Modified and reproduced
with permission from the American Heart Association.18
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Illustration of the effects of the boronate-type proteasome inhibitor, bortezomib, at low and
high dose on the composition of advanced atherosclerotic plaques in ApoE-deficient mice
including an increase in immunoreactivity for cleaved caspase-3 and a decrease for α-SMC-
actin+cells, a decrease in collagen content by Sirius red staining, and an increase in necrotic
core size by hematoxylin eosin (HE) staining; *p<0.05, **p<0.01 versus control; scale
bar=50 μm. Modified and reproduced with permission from Springer Verlag.63
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In patients with fatal myocardial infarction, an increase in ubiquitin immunoreactivity is
evident in the complicated plaques of the infarction-related coronary arteries compared with
advanced plaques in the noninfarction-related coronary arteries. The difference in ubiquitin
immunoreactivity is notable in the shoulder and fibrous cap areas (left panels). In patients
undergoing carotid endarterectomy, immunoblotting-determined levels of ubiquitin–protein
conjugates, but not free ubiquitin, are higher and chymotrypsin-like proteasome activity is
lower in plaques from patients with symptoms of transient ischemic attack (TIA), stroke, or
amaurosis (Am.) fugax within 6 months of surgery (right panel). Reproduced with
permission from Elsevier.65
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Illustration of the role of the ubiquitin–proteasome system in protein quality aspects of
atherosclerosis. In the initial phase of cardiovascular risk factor exposure, compensatory
upregulation of chaperones and the ubiquitin–proteasome system prevents the overwhelming
intracellular accumulation of damaged and dysfunctional proteins. The ubiquitin–
proteasome system also contributes to the classical activation pathway of nuclear factor
kappa-B and thereby to inflammation and cell proliferation. With the formation and growth
of a metabolically active atherosclerotic plaque, there is further production of misfolded and
damaged proteins in the progression phase. Once the classical protein quality mechanisms
are overwhelmed and fail, these dysfunctional proteins accumulate (and aggregate) and
autophagy remains the final clearance pathway. The accumulating proteins can undergo
further oxidation, ubiquitination, and cross-linking. Furthermore, beta-pleated sheets can be
formed and hence amyloid fibrils. In addition to intracellular proteins, proteins in the
extracellular matrix can undergo conformational changes. For instance, oxidation and
phospholipid hydrolysis of low-density lipoprotein (LDL) produces oxidatively modified
and electronegative particles with unfolding of the apolipoprotein components. The
generation of amyloid-like structures in this process serves as a potent “key” to the uptake of
these modified LDLs by macrophages via scavenger receptors. Recognition of amyloid-like
fibrils by CD36 leads to the production of reactive oxygen species, chemokines, and
cytokines, which contributes further to the atherosclerotic disease process, including its
complication phase. Reproduced with permission from Elsevier.65
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Potential roles for the UPS and 11S-activated proteasome in short- and long-duration
ischemia. In the nonischemic heart, oxidized, misfolded, and ubiquitinated proteins are
degraded through both ubiquitin- and nonubiquitin-mediated pathways, recycling the
constituent amino acids, and maintaining a dynamic balance between pro-survival and pro-
death signals. During an ischemic insult resulting in cell death or dysfunction, UPS function
is inhibited leading to accumulation of oxidized and ubiquitinated proteins. In addition, a
condition known as dysregulation may occur in which normal UPS-mediated degradation of
pro-death proteins is depressed. Reproduced with permission from Oxford University
Press.214
Powell et al. Page 44
Prog Mol Biol Transl Sci. Author manuscript; available in PMC 2013 August 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
